Cytokinetics Announced The Primary Results From ACACIA-HCM (Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-obstructive HCM), The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy